A Study to Assess the Pharmacokinetics and Safety of PT010 in Subjects With Moderate to Severe COPD Following Single and Repeat Dose Administration
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2018
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Pearl Therapeutics
- 21 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2018 Planned End Date changed from 21 Dec 2017 to 18 Apr 2018.
- 16 Aug 2017 New trial record